Gene therapy Vaccine therapy Studying and testing new mesothelioma treatments is key in helping cancer patients and hopefully finding a cure. By accessing new treatments through a clinical trial, some mesothelioma patients may be able to live longer or with less pain — even if their cancer doesn...
Experimental new treatment options for mesothelioma include advances such as cancer vaccines, enzyme therapy, gene therapy and virotherapy. These promising treatments may provide hope for patients who don’t respond to standard therapies. Traditional treatments help people with mesothelioma cancer live long...
You are designing a new ionizing radiation therapy for mesothelioma patients. This new therapy leads to a cell cycle arrest that monitors completion of DNA replication. Which checkpoint is affected by your ionizing radiation therapy? Can surgery successfully cure a patient of cancer that has...
Cohen Cystic mesothelioma of the peritoneum Rajiv V. Datta, Philip B. Paty Wound Tissue Oxygen Tension Predicts the Risk of Wound Infection in Surgical Patients Harriet W. Hopf, Thomas K. Hunt, Judith M. West, Peter Blomquist, William H. Goodson, J. Arthur Jensen, Kent Jonsson, Philip B....
Other cancers may also be targeted with this new approach, e.g., hard-to-treat cancers such as mesothelioma and pancreatic cancer. In order to attack large tumors with adoptive cellular therapy, it seems pivotal that the T cells proliferate to achieve an appropriate effector-to-target cell rat...
Cancer, ranked as the second leading cause of mortality worldwide, leads to the death of approximately seven million people annually, establishing itself as one of the most significant health challenges globally. The discovery and identification of new a
1. The median progression free survival (PFS) for patients enrolled was 2.83 months (95% CI: 2.53–3.98) with a maximum of up to 10.5 months in this advanced/metastatic mesothelioma population. Fig. 1 Change in tumor size at best response Full size image Safety In total, 40 of the 42 ...
Existing MSC-based therapies have problems with cell survival, regenerative ability, immune response, and the possibility of differentiation into tumors. These problems can be prevented by utilizing exosomes as a cell-free therapy; for instance, as exosomes cannot proliferate, there is no possibility ...
Kaira K, Oriuchi N, Takahashi T, Nakagawa K, Ohde Y, Okumura T, Murakami H, Shukuya T, Kenmotsu H, Naito T, Kanai Y, Endo M, Kondo H, Nakajima T, Yamamoto N: L-type amino acid transporter 1 (LAT1) expression in malignant pleural mesothelioma. Anticancer Res. 2011, 31: 4075-...
In addition, positive clinical trial results with Dual immune checkpoint blockade have also attracted the interest of investigators [12], and the FDA has approved ipilimumab plus nivolumab for melanoma, RCC, MSI-H/dMMR colorectal cancer, HCC, PD-L1-positive NSCLC and malignant pleural mesothelioma...